Oxford BioMedica has signed a three-year contract to manufacture and supply viral vectors to support Boehringer Ingelheim’ s cell and gene therapy pipeline. Under the terms of the Development and Supply Agreement (DSA), Oxford BioMedica will manufacture batches for German pharmaceutical company Boehringer Ingelheim. The agreement also enables Oxford BioMedica to produce and supply viral vector products in the future. The manufacturing will take place at Oxford BioMedica’s Windrush Court site, located in Oxford, UK as well as at one…